NAYAX LTD (NYAX)

IL0011751166 - Common Stock

30.025  +0.86 (+2.97%)

Fundamental Rating

3

Taking everything into account, NYAX scores 3 out of 10 in our fundamental rating. NYAX was compared to 126 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of NYAX have multiple concerns. NYAX is valued quite expensive, but it does show an excellent growth.



1

1. Profitability

1.1 Basic Checks

In the past year NYAX has reported negative net income.
NYAX had negative earnings in each of the past 5 years.
In multiple years NYAX reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -3.93%, NYAX is in line with its industry, outperforming 41.32% of the companies in the same industry.
With a Return On Equity value of -10.04%, NYAX is not doing good in the industry: 60.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -3.93%
ROE -10.04%
ROIC N/A
ROA(3y)-10.88%
ROA(5y)-9.39%
ROE(3y)-23.64%
ROE(5y)-31.36%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of NYAX (37.49%) is better than 64.46% of its industry peers.
NYAX's Gross Margin has declined in the last couple of years.
NYAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.38%
GM growth 5Y-3.01%

3

2. Health

2.1 Basic Checks

NYAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NYAX has more shares outstanding than it did 1 year ago.
The debt/assets ratio for NYAX is higher compared to a year ago.

2.2 Solvency

NYAX has an Altman-Z score of 3.07. This indicates that NYAX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NYAX (3.07) is comparable to the rest of the industry.
NYAX has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.39, NYAX is not doing good in the industry: 66.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z 3.07
ROIC/WACCN/A
WACC9.11%

2.3 Liquidity

NYAX has a Current Ratio of 1.36. This is a normal value and indicates that NYAX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.36, NYAX is doing worse than 86.78% of the companies in the same industry.
NYAX has a Quick Ratio of 1.27. This is a normal value and indicates that NYAX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of NYAX (1.27) is worse than 70.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.27

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.84% over the past year.
NYAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.72%.
Measured over the past years, NYAX shows a very strong growth in Revenue. The Revenue has been growing by 37.05% on average per year.
EPS 1Y (TTM)49.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%121.51%
Revenue 1Y (TTM)35.72%
Revenue growth 3Y44.05%
Revenue growth 5Y37.05%
Sales Q2Q%37.59%

3.2 Future

Based on estimates for the next years, NYAX will show a very strong growth in Earnings Per Share. The EPS will grow by 70.19% on average per year.
NYAX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.41% yearly.
EPS Next Y46.54%
EPS Next 2Y69.61%
EPS Next 3Y70.19%
EPS Next 5YN/A
Revenue Next Year38.74%
Revenue Next 2Y33.76%
Revenue Next 3Y32.41%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NYAX. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 71.80, the valuation of NYAX can be described as expensive.
NYAX's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.59, NYAX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 71.8

4.2 Price Multiples

NYAX's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1657.4

4.3 Compensation for Growth

NYAX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NYAX's earnings are expected to grow with 70.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.61%
EPS Next 3Y70.19%

0

5. Dividend

5.1 Amount

No dividends for NYAX!.
Industry RankSector Rank
Dividend Yield N/A

NAYAX LTD

NASDAQ:NYAX (1/2/2025, 10:30:29 AM)

30.025

+0.86 (+2.97%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)11-12 2024-11-12/dmh
Earnings (Next)N/A N/A
Inst Owners19.02%
Inst Owner Change6.06%
Ins Owners68.83%
Ins Owner ChangeN/A
Market Cap1.10B
Analysts80
Price Target0.4 (-98.67%)
Short Float %0.73%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-354.41%
Min EPS beat(2)-620.59%
Max EPS beat(2)-88.24%
EPS beat(4)2
Avg EPS beat(4)-174.25%
Min EPS beat(4)-620.59%
Max EPS beat(4)9.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.6%
Min Revenue beat(2)-11.8%
Max Revenue beat(2)-3.39%
Revenue beat(4)0
Avg Revenue beat(4)-5.39%
Min Revenue beat(4)-11.8%
Max Revenue beat(4)-2.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.01%
PT rev (3m)88.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 71.8
P/S 4.65
P/FCF N/A
P/OCF N/A
P/B 6.92
P/tB 17.9
EV/EBITDA 1657.4
EPS(TTM)-0.31
EYN/A
EPS(NY)0.42
Fwd EY1.39%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS6.46
BVpS4.34
TBVpS1.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.93%
ROE -10.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.49%
FCFM N/A
ROA(3y)-10.88%
ROA(5y)-9.39%
ROE(3y)-23.64%
ROE(5y)-31.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.38%
GM growth 5Y-3.01%
F-ScoreN/A
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA 110.4
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.36
Quick Ratio 1.27
Altman-Z 3.07
F-ScoreN/A
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)19.45%
Cap/Depr(5y)66.03%
Cap/Sales(3y)1.12%
Cap/Sales(5y)4.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%121.51%
EPS Next Y46.54%
EPS Next 2Y69.61%
EPS Next 3Y70.19%
EPS Next 5YN/A
Revenue 1Y (TTM)35.72%
Revenue growth 3Y44.05%
Revenue growth 5Y37.05%
Sales Q2Q%37.59%
Revenue Next Year38.74%
Revenue Next 2Y33.76%
Revenue Next 3Y32.41%
Revenue Next 5YN/A
EBIT growth 1Y62.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year410.61%
EBIT Next 3Y117.77%
EBIT Next 5YN/A
FCF growth 1Y128.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y131.94%
OCF growth 3Y10.69%
OCF growth 5Y36.82%